NCT01749384View on ClinicalTrials.gov

Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 6, 2012

Primary Completion Date

May 24, 2016

Study Completion Date

May 24, 2016

Conditions

Solid Neoplasm

Interventions

BIOLOGICAL

Bevacizumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Tivantinib

Given PO

Trial Locations (2)

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

17033-0850

Penn State Milton S Hershey Medical Center, Hershey

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT01749384 - Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | Biotech Hunter | Biotech Hunter